These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1910430)

  • 21. Cyclosporin pharmacokinetics following administration of capsules and Neoral in paediatric patients with lupus nephritis.
    Fu LW; Yang LY; Chen WP; Lin CY
    Br J Clin Pharmacol; 1997 Aug; 44(2):125-7. PubMed ID: 9278195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD.
    Kirchner GI; Winkler M; Mueller L; Vidal C; Jacobsen W; Franzke A; Wagner S; Blick S; Manns MP; Sewing KF
    Br J Clin Pharmacol; 2000 Nov; 50(5):449-54. PubMed ID: 11069439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of significant interaction of fluconazole with cyclosporin.
    Krüger HU; Schuler U; Zimmermann R; Ehninger G
    J Antimicrob Chemother; 1989 Nov; 24(5):781-6. PubMed ID: 2557319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclosporin-erythromycin interaction in renal transplant patients.
    Gupta SK; Bakran A; Johnson RW; Rowland M
    Br J Clin Pharmacol; 1989 Apr; 27(4):475-81. PubMed ID: 2655690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ocular penetration of cyclosporin A. The rabbit eye.
    BenEzra D; Maftzir G
    Invest Ophthalmol Vis Sci; 1990 Jul; 31(7):1362-6. PubMed ID: 2365566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients.
    Kasiske BL; Heim-Duthoy K; Rao KV; Awni WM
    Transplantation; 1988 Nov; 46(5):716-22. PubMed ID: 3057694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclosporine (cyclosporin A) pharmacokinetics in renal transplant patients receiving ciprofloxacin.
    Lang J; Finaz de Villaine J; Garraffo R; Touraine JL
    Am J Med; 1989 Nov; 87(5A):82S-85S. PubMed ID: 2589391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclosporin A blood levels are not influenced by dietary alterations in lipids.
    Menon SP; Walker RJ; Duggin GG; Sullivan DR; Horvath JS; Tiller DJ
    Res Commun Chem Pathol Pharmacol; 1991 May; 72(2):203-12. PubMed ID: 1876751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concentration-guided strategies in drug development: experience with a cyclosporine analog in transplantation.
    Kovarik JM; Mueller EA; Kallay Z; Smith HT; Lison AE; Arns W; Renner E
    J Clin Pharmacol; 1995 Dec; 35(12):1136-43. PubMed ID: 8750363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation.
    Lindholm A; Dahlqvist R; Groth GG; Sjöqvist F
    Br J Clin Pharmacol; 1990 Sep; 30(3):443-52. PubMed ID: 2223423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group.
    Barone G; Chang CT; Choc MG; Klein JB; Marsh CL; Meligeni JA; Min DI; Pescovitz MD; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL
    Transplantation; 1996 Mar; 61(6):875-80. PubMed ID: 8623152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects. A single, randomized, two-way cross-over, open-label phase I study.
    Izquierdo I; Borja J; Rovira S; Pelagio P; Torres F; Cebrecos J; García-Rafanell J
    Arzneimittelforschung; 2010; 60(1):36-41. PubMed ID: 20184225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay.
    Kahan BD; Kramer WG; Wideman C; Flechner SM; Lorber MI; Van Buren CT
    Transplantation; 1986 Apr; 41(4):459-64. PubMed ID: 3515645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of cyclosporin A in whole blood and plasma in five patients with different hematocrits.
    Agarwal RP; McPherson RA; Threatte GA
    Ther Drug Monit; 1985; 7(1):61-5. PubMed ID: 3887670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Saturable binding of cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment.
    Legg B; Rowland M
    Pharm Res; 1988 Feb; 5(2):80-5. PubMed ID: 3073383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants.
    Undre N; Dickinson J
    BMJ Open; 2017 Apr; 7(4):e012252. PubMed ID: 28377389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effective long-term immunosuppression maintained by low cyclosporine levels in primary cadaveric renal transplant recipients.
    Kupin WL; Venkat KK; Norris C; Florence-Green D; Dienst S; Oh HK; Feldkamp C; Levin NW
    Transplantation; 1987 Feb; 43(2):214-8. PubMed ID: 3544378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered pharmacokinetics of cyclosporin in heart-lung transplant recipients with cystic fibrosis.
    Tan KK; Hue KL; Strickland SE; Trull AK; Smyth RL; Scott JP; Kelman AW; Whiting B; Higenbottam TW; Wallwork J
    Ther Drug Monit; 1990 Nov; 12(6):520-4. PubMed ID: 2274997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms.
    Yue CS; Scarsi C; Ducharme MP
    Arzneimittelforschung; 2012 Dec; 62(12):631-6. PubMed ID: 23154888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.